XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - Summary of Revenues Disaggregated by Product Classification and Reportable Segment (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Disaggregation Of Revenue [Line Items]        
Total revenue $ 27,198 $ 26,106 $ 52,131 $ 49,109
Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 15,350 13,964 29,584 26,308
Royalties [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 9,429 9,844 18,194 17,943
Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2,419 2,298 4,353 4,858
Operating Segments [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 27,198 26,106 52,131 49,109
Operating Segments [Member] | Medical Device [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 19,707 18,453 38,725 35,361
Operating Segments [Member] | Medical Device [Member] | Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 7,914 6,441 16,294 13,229
Operating Segments [Member] | Medical Device [Member] | Royalties [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 8,073 8,358 15,482 15,244
Operating Segments [Member] | Medical Device [Member] | License Fees [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 1,356 1,486 2,712 2,699
Operating Segments [Member] | Medical Device [Member] | Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2,364 2,168 4,237 4,189
Operating Segments [Member] | In Vitro Diagnostics [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 7,491 7,653 13,406 13,748
Operating Segments [Member] | In Vitro Diagnostics [Member] | Product Sales [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 7,436 7,523 13,290 13,079
Operating Segments [Member] | In Vitro Diagnostics [Member] | Research, Development and Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue $ 55 $ 130 $ 116 $ 669